Discussion on Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- To date, this was the first in-human clinical trial of a novel Ad5 vectored COVID-19 vaccine. The vaccine was tolerated in health adults in all three dosage groups. The high dose group did experience more severe reactions to the vaccine, but were transient and self-limiting. The low and middle dose would be further tested in a future clinical trial.
- "There was a strong positive correlation between binding antibodies and neutralizing antibody titers to the live virus."
- Currently, there is not enough about the roles of specific antibodies or T cells to predict the protection of the Ad5 vectored COVID-19 vaccine. However, the previous studies done on SARS and MERS saw a rapid decline in specific antibodies after recovery, similar to the results achieved in this study.
- Additional follow up on the vaccine recipients for at least 6 months will be done to gather additional data.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Methods for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Results for Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Discussion on Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial